Medical Innovations Pathways Takes the Stage at Granite School District’s Career Night
January 25, 2019
Yesterday, Utah’s life sciences companies participating in the Medical Innovations Pathways (MIP) program (www.medicalinnovationspathways.com), gathered at Granite School District as part of the district’s annual Career and Technical Education Open House. The Open House offers students a glimpse into a board range of industries. Representatives from BD, Edwards Lifesciences, Merit Medical, Nelson Laboratories, and Stryker set up company exhibits and made presentations during special medical device and laboratory testing breakout sessions.
“it was a great night,” said Jake Willis, Project Portfolio Manager with Nelson Laboratories. “We were able to talk directly to students and their parents, and help them understand what working in the life sciences industry is all about.”
The MIP program provides students with the opportunity to directly engage with leaders of Utah’s life sciences industry, and earn the Medical Innovations Certificate.
“We want students to enroll in MIP and come visit our facilities,” said Anthea Alono, Human Resources Director for Stryker. “Ultimately, we hope they come work for us and share in our passions for innovation and saving lives.”
The MIP program, now in its third year, is offered to high school seniors in Alpine, Canyons, Davis, Granite, Jordan, and Tooele school districts. In addition to completing required MIP coursework, students enrolled in the program will do company job shadows.
Recent News
- Improving Women’s Health: MobileODT Joins Liger Medical
- Wasatch Health Announces Structured Capital Fund
- Seek Labs Announces Inclusion of Veterinary Diseases in Global Disease Atlas, Accelerating Development of Therapeutics to Bolster Global Protein Supply Chains
- Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
- Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)